Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cardiome Pharma Corp. (NASDAQ: CRME).

Full DD Report for CRME

You must become a subscriber to view this report.


Recent News from (NASDAQ: CRME)

Cardiome Pharma's (CRME) CEO William Hunter on Q1 2018 Results - Earnings Call Transcript
Cardiome Pharma Corporation (CRME) Q1 2018 Earnings Conference Call May 15, 2018, 04:30 PM ET Executives Justin Renz - CFO David Dean - Chief Business Development Officer William Hunter - President, CEO & Director Analysts Dewey Steadman - Canaccord Genuity Sean Lee -...
Source: SeekingAlpha
Date: May, 15 2018 22:14
Cardiome Pharma misses by $0.16, beats on revenue
Cardiome Pharma (NASDAQ: CRME ): Q1 EPS of -$0.24 misses by $0.16 . More news on: Cardiome Pharma Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 15 2018 16:18
Correvio Reports First Quarter 2018 Financial Results
Correvio Reports First Quarter 2018 Financial Results Canada NewsWire VANCOUVER, May 15, 2018 Management to Host Conference Call and Webcast Today, May 15, 2018 at 4:30 p.m. Eastern ( 1:30 p.m. Pacific) NASDAQ: CRME  TSX: COM VANCOUVER , May 15, 2018 /CNW...
Source: Canada Newswire
Date: May, 15 2018 16:00
Correvio Pharma Corp Completes Strategic Transaction with Cipher Pharmaceuticals
NASDAQ: CRME   TSX: COM Cardiome Pharma Corp. Becomes Correvio Pharma Corp., Closes on $25.5 million (CAD) in Non-Dilutive Capital VANCOUVER , May 15, 2018 /PRNewswire/ - Correvio Pharma Corp. ("Correvio"), formerly Cardiome Pharma Corp. ("Cardiome") (NASDAQ:CRME ...
Source: PR Newswire
Date: May, 15 2018 08:40
Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference Call
Shareholders Approve Cipher Acquisition of Canadian Business Portfolio of Cardiome Company to Host First Quarter 2018 Financial Results Conference Call on Tuesday, May 15, 2018 at 4:30 p.m. ET NASDAQ: CRME TSX: COM VANCOUVER , May 10, 2018 /PRNewswire/ - Cardiome Pharma C...
Source: PR Newswire
Date: May, 10 2018 07:00
Cardiome up 13% premarket on United Therapeutics' takeout of SteadyMed
Thinly traded nano cap Cardiome (NASDAQ: CRME ) is up  13%  premarket on light volume on the heels of United Therapeutics' planned acquisition of SteadyMed that includes a contingent amount of $75M based on the commercialization of drug-device Trevyent. More news on: Cardiome Pha...
Source: SeekingAlpha
Date: April, 30 2018 09:10
Cardiome to Present at the Bloom Burton & Co. Healthcare Investor Conference
NASDAQ:CRME, TSX:COM VANCOUVER , April 26, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Mr. David Dean , Chief Business Development Officer of ...
Source: PR Newswire
Date: April, 26 2018 16:33
Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess®
NASDAQ: CRME   TSX: COM VANCOUVER , April 17, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced completion of enrollment for the Pha...
Source: PR Newswire
Date: April, 17 2018 08:00
Key events next week - healthcare
Noteworthy events during the week of April 15 - 21 for healthcare investors. More news on: Bristol-Myers Squibb Company, Biondvax Pharmaceuticals, Rigel Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: April, 13 2018 09:56
Cardiome Announces Fifteen Xydalba(TM) and Zevtera® Abstracts at ECCMID 2018
Cardiome Announces Fifteen Xydalba™ and Zevtera® Abstracts at ECCMID 2018 Canada NewsWire VANCOUVER, April 12, 2018 NASDAQ: CRME   TSX: COM Company Will Also Host Xydalba Expert Educational Session Featuring Key Opinion Leaders in the Field of Ho...
Source: Canada Newswire
Date: April, 12 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-162.402.312.452.3089,952
2018-05-152.372.362.402.3446,966
2018-05-142.272.372.382.26102,976
2018-05-112.272.272.302.2777,060
2018-05-102.302.28492.322.2710,010

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-166,67347,50814.0461Cover
2018-05-1515,06434,84643.2302Short
2018-05-1423,66580,58329.3672Cover
2018-05-117,34669,44310.5785Cover
2018-05-103224,9626.4893Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CRME.


About Cardiome Pharma Corp. (NASDAQ: CRME)

Logo for Cardiome Pharma Corp. (NASDAQ: CRME)

Not available

 

Contact Information

 

 

Current Management

  • Robert Rieder / President, CEO
  • Doug Janzen / CFO

Current Share Structure

  • Market Cap: $82,436,803 - 05/15/2018
  • Issue and Outstanding: 34,637,312 - 12/31/2017

 


Recent Filings from (NASDAQ: CRME)

Post-effective amendment to an S-8 filing
Filing Type: S-8 POSFiling Source: edgar
Filing Date: May, 15 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 15 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 15 2018
Notice of securities of successor issuers deemed registered
Filing Type: 8-K12G3Filing Source: edgar
Filing Date: May, 15 2018
Post-effective amendment to an S-8 filing
Filing Type: S-8 POSFiling Source: edgar
Filing Date: May, 15 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 15 2018
Certification of termination of registration of a class of security under Section 12(g) or notice of suspension of duty to file reports under Section 13 and 15(d) of the Act Section 12 (g).
Filing Type: 15-12GFiling Source: edgar
Filing Date: May, 15 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 11 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 10 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: May, 02 2018

 

 


Daily Technical Chart for (NASDAQ: CRME)

Daily Technical Chart for (NASDAQ: CRME)


Stay tuned for daily updates and more on (NASDAQ: CRME)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CRME)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CRME is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CRME and does not buy, sell, or trade any shares of CRME. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/